– Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th- Additional $20 million in cash with an additional future option of $20 million through Oxford loan ame… […]
CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces that Michael Poirier, President, Chief Executive Officer and Chairman, has issued a letter to Qualigen’s stockholders. The full text is as follows:… […]
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the firs… […]
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cur… […]
Recently announced AWARE-1 data further support the potential of pelareorep to induce a durable anti-tumor immune memory effect and improve outcomes in breast cancerInitiated dosing in phase 2 IRENE study evaluating pelareorep-anti-PD-1 combination tre… […]
LA JOLLA, Calif., Nov. 10, 2020 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today repo… […]
Launched Phexxi(TM) (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free ContraceptionInitiated Pivotal Phase 3 EVOGUARD Trial of EVO100 for Prevention of Chlamydia and GonorrheaSecured $25 Million Strategic Investment from Adjuvan… […]
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $254 million with Approximately 45,100 TRxONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” EpisodesInitiating Phas… […]
First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (“ADPKD”)Restructuring of Sanofi and Oxford AgreementsReceipt of $5 Million Milestone and Material Payments from … […]
First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (“ADPKD”)Restructuring of Sanofi and Oxford AgreementsReceipt of $5 Million Milestone and Material Payments from … […]
Copyright © 2021 | MH Magazine WordPress Theme by MH Themes
